Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$40.04

-0.14 (-0.35%)

06:46
10/02/18
10/02
06:46
10/02/18
06:46

GlaxoSmithKline: Albiglutude 'superior' to placebo in Harmony Outcomes study

GSK and the Duke Clinical Research Institute announced publication of results from the Harmony Outcomes study which assessed the cardiovascular safety and efficacy of albiglutide, a GLP-1 receptor agonist, in patients with type 2 diabetes and cardiovascular disease. Results were presented at the European Association for the Study of Diabetes congress 2018 with simultaneous publication in The Lancet. The study was initiated in July 2015 and GSK remained committed to completing it following an announcement in July 2017 of GSK's intention to cease further R&D, manufacturing and sales activity for albiglutide. Prior studies of GLP-1 receptor agonists when used in patients with diabetes and CV disease had provided inconsistent results regarding the potential benefit, and GSK believed that the data generated from this study could contribute important new evidence to the field. The primary outcome showed that albiglutide, administered subcutaneously once-weekly in 9463 patients over a median period of 1.6 years, was superior to placebo in reducing the risk of major adverse cardiovascular events by 22% when used in addition to standard of care in patients with type 2 diabetes and cardiovascular disease. Dr John Lepore, Senior Vice President R&D Pipeline, GSK said: "Harmony Outcomes was an important study for us to complete to generate new data and insights about the role of the GLP-1 receptor agonist class in the management of patients with diabetes and cardiovascular disease. GSK continued to invest in this study following a decision last year to cease all other activities on albiglutide, and we continue to explore opportunities to divest this medicine to a company with the right expertise and resources to realise its full potential for patients."

  • 03

    Oct

  • 03

    Oct

GSK GlaxoSmithKline
$40.04

-0.14 (-0.35%)

08/15/18
RBCM
08/15/18
NO CHANGE
RBCM
Outperform
RBC says Gilead weakness on CMO leaving, Glaxo data a buying opportunity
RBC Capital analyst Brian Abrahams believes Gilead's (GILD) weakness is potentially due to data from GlaxoSmithKline's (GSK) ATLAS trial and last night's announcement of the departure of its CMO. However, he does not see either as a major fundamental concern and would use the weakness in Gilead shares as a buying opportunity. Feedback he has received from doctors is that injectables like Glaxo's could be used in a select number of patients, but he does not see a major impact on Gilead's HIV franchise near- or long-term from this product, Abrahams said. On the CMO departure, the analyst said that the company clarified that this is "completely unrelated" to the recently-announced CEO transition, so he does not see this reflecting any major structural issue. Abrahams keeps an Outperform rating on Gilead shares, which are down over 3% to $74.82 in afternoon trading.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/30/18
08/30/18
DOWNGRADE

GlaxoSmithKline downgraded to Hold from Buy at Liberum
Liberum analyst Roger Franklin downgraded GlaxoSmithKline to Hold while raising his price target for the shares to GBP 17 from GBP 16.30. The analyst believes the company's improved research and development is now priced into the shares and he sees less upside going forward.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.

TODAY'S FREE FLY STORIES

KOF

Coca-Cola Femsa

$59.41

-1.75 (-2.86%)

09:36
10/23/18
10/23
09:36
10/23/18
09:36
Upgrade
Coca-Cola Femsa rating change  »

Coca-Cola Femsa upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$47.93

0.34 (0.71%)

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Oracle initiated  »

Oracle initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 14

    Nov

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Conference/Events
JPMorgan European & EMEA analysts to hold analyst/industry conference call »

European Utilities…

ABBV

AbbVie

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
AbbVie initiated  »

AbbVie initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

SNY

Sanofi

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Sanofi initiated  »

Sanofi reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

RHHBY

Roche

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Roche initiated  »

Roche reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 24

    Dec

09:35
10/23/18
10/23
09:35
10/23/18
09:35
General news
Treasury 2-year auction outlook: the $38 B 2-year sale »

Treasury 2-year auction…

PFE

Pfizer

$44.37

-0.13 (-0.29%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Pfizer initiated  »

Pfizer reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

GSK

GlaxoSmithKline

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
GlaxoSmithKline initiated  »

GlaxoSmithKline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

  • 07

    Nov

LLY

Eli Lilly

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Eli Lilly initiated  »

Eli Lilly reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

NVS

Novartis

$87.12

-0.07 (-0.08%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Novartis initiated  »

Novartis reinitiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MRK

Merck

$72.56

0.22 (0.30%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Merck initiated  »

Merck reinitiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$50.87

-3.44 (-6.33%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Bristol-Myers initiated  »

Bristol-Myers reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 20

    May

AZN

AstraZeneca

$39.50

0.295 (0.75%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
AstraZeneca initiated  »

AstraZeneca reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Nov

MLCO

Melco Resorts & Entertainment

$17.74

-0.04 (-0.22%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Downgrade
Melco Resorts & Entertainment rating change  »

Melco Resorts &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$26.10

-0.56 (-2.10%)

, BAC

Bank of America

$27.36

-0.95 (-3.36%)

09:33
10/23/18
10/23
09:33
10/23/18
09:33
Technical Analysis
Technical Take: Bank of America drops in early trading »

The shares were last down…

XLF

Financial Select Sector

$26.10

-0.56 (-2.10%)

BAC

Bank of America

$27.36

-0.95 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

UTX

United Technologies

$126.42

-2.22 (-1.73%)

09:33
10/23/18
10/23
09:33
10/23/18
09:33
Hot Stocks
United Technologies says geo-political outlook is the biggest concern »

Says tariffs present a 5c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

UBS

UBS

$13.77

-0.085 (-0.61%)

09:32
10/23/18
10/23
09:32
10/23/18
09:32
Periodicals
UBS backs down warning to staff about traveling to China, FT reports »

UBS has rescinded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$12.50

0.35 (2.88%)

09:31
10/23/18
10/23
09:31
10/23/18
09:31
Hot Stocks
eXp Realty to acquire ShowMeNow, terms not disclosed »

eXp Realty, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

HOG

Harley-Davidson

$38.72

-0.84 (-2.12%)

09:31
10/23/18
10/23
09:31
10/23/18
09:31
Hot Stocks
Harley-Davidson says FY18 shipments will finish at low-end of guidance range »

Management says adapting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ORCL

Oracle

$47.93

0.34 (0.71%)

, AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

09:30
10/23/18
10/23
09:30
10/23/18
09:30
Periodicals
Move from Oracle cause of Amazon warehouse outage on Prime Day, CNBC says »

Amazon (AMZN) dealt with…

ORCL

Oracle

$47.93

0.34 (0.71%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 14

    Nov

HAL

Halliburton

$36.36

-1.18 (-3.14%)

09:30
10/23/18
10/23
09:30
10/23/18
09:30
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAN

Huntington Bancshares

$13.66

-0.54 (-3.80%)

09:27
10/23/18
10/23
09:27
10/23/18
09:27
Hot Stocks
Huntington Bancshares to make targeted investments in people, technology »

Says local economies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

YMAB

Y-mAbs Therapeutics

$22.00

0.02 (0.09%)

09:27
10/23/18
10/23
09:27
10/23/18
09:27
Hot Stocks
Y-mAbs Therapeutics receives recommendation from COMP for OMPD for naxitamab »

Y-mAbs Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$6.84

0.02 (0.29%)

09:26
10/23/18
10/23
09:26
10/23/18
09:26
Upgrade
Snap rating change  »

Snap upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.